当前位置: X-MOL 学术Am. J. Gastroenterol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
The American Journal of Gastroenterology ( IF 8.0 ) Pub Date : 2022-04-15 , DOI: 10.14309/ajg.0000000000001795
Neeraj Narula 1 , Emily C L Wong 1 , Parambir S Dulai 2 , John K Marshall 1 , Vipul Jairath 3 , Walter Reinisch 4
Affiliation  

INTRODUCTION We compared the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohn's disease (CD). METHODS This was a pooled analysis of patient-level data from 299 patients with CD from 4 clinical trials. Proportions of patients treated with each biologic were compared for achieving 1-year complete EH (Simple Endoscopic Score for CD [SES-CD] <3) and ileal and colonic EH separately (SES-CD = 0). Multivariate logistic regression was used to model the relationship between biologics and 1-year outcomes and adjusted for disease duration, concomitant corticosteroid use, and prior antitumor necrosis factor failure. RESULTS Compared with vedolizumab (4/56 [7.1%]), adalimumab (17/61 [27.9%], adjusted odds ratio [OR]: 5.79, 95% confidence interval [CI]: 1.77-18.95, P = 0.004) and infliximab (39/141 [27.7%], aOR: 4.59, 95% CI: 1.48-14.22, P = 0.008) had superior rates of 1-year EH. No significant difference was observed between vedolizumab and ustekinumab. Similar results were observed among biologic-naive patients. Among patients with baseline ileal SES-CD ≥3, no significant differences were observed between biologics for 1-year ileal EH. However, for large (>0.5 cm) ileal ulcers, infliximab (20/49 [40.8%]) had superior rates of no ileal ulcers compared with vedolizumab (2/23 [8.7%], aOR: 5.39, 95% CI: 1.03-28.05, P = 0.045). No other differences were observed. For colonic disease, compared with ustekinumab (9/31 [29.0%]), adalimumab (30/48 [62.5%], aOR: 3.97, 95% CI: 1.45-10.90, P = 0.007) had superior rates of 1-year EH in the colon, with similar trends observed for infliximab (55/105 [52.4%], aOR: 2.08, 95% CI: 0.82-5.27, P = 0.121). No other differences were observed. DISCUSSION In this post hoc analysis, TNF-α antagonists were overall superior to vedolizumab and ustekinumab for achieving 1-year EH in moderate-severe CD patients.

中文翻译:

生物制剂对克罗恩病中回肠和结肠内镜愈合的比较疗效。

引言 我们比较了阿达木单抗、英夫利昔单抗、优特克单抗和维多珠单抗对中重度克罗恩病 (CD) 治疗 1 年后内镜下愈合 (EH) 能力的疗效。方法 这是对来自 4 项临床试验的 299 名 CD 患者的患者水平数据的汇总分析。分别比较了接受每种生物制剂治疗的患者比例,以实现 1 年完全 EH(CD 的简单内镜评分 [SES-CD] <3)和回肠和结肠 EH(SES-CD = 0)。多变量逻辑回归用于模拟生物制剂与 1 年结果之间的关系,并根据疾病持续时间、伴随的皮质类固醇使用和先前的抗肿瘤坏死因子失败进行了调整。结果 与维多珠单抗(4/56 [7.1%])、阿达木单抗(17/61 [27.9%])相比,调整优势比 [OR]:5.79,95% 置信区间 [CI]: 1.77-18.95, P = 0.004) 和英夫利昔单抗 (39/141 [27.7%], aOR: 4.59, 95% CI: 1.48-14.22, P = 0.008) 的 1 年率更高嗯。维多珠单抗和优特克单抗之间未观察到显着差异。在未使用生物制剂的患者中也观察到了类似的结果。在基线回肠 SES-CD ≥3 的患者中,1 年回肠 EH 的生物制剂之间未观察到显着差异。然而,对于较大的(>0.5 cm)回肠溃疡,英夫利昔单抗(20/49 [40.8%])与维多珠单抗相比具有更高的无回肠溃疡发生率(2/23 [8.7%],aOR:5.39,95% CI:1.03 -28.05,P = 0.045)。没有观察到其他差异。对于结肠疾病,与优特克单抗 (9/31 [29.0%]) 相比,阿达木单抗 (30/48 [62.5%], aOR: 3.97, 95% CI: 1.45-10.90, P = 0.007) 的 1 年发生率更高结肠中的 EH,英夫利昔单抗的趋势相似(55/105 [52.4%],aOR:2.08,95% CI:0.82-5.27,P = 0.121)。没有观察到其他差异。讨论 在这项事后分析中,在中重度 CD 患者中,TNF-α 拮抗剂在实现 1 年 EH 方面总体上优于维多珠单抗和优特克单抗。
更新日期:2022-04-15
down
wechat
bug